ALFA Finder| Revenue growth | 310% YoY growth in revenue from operations to ₹408.4 Cr. |
|---|---|
| Margins | EBITDA margin at 25.2% (Q1 FY27) vs -14.4% (Q1 FY26). |
| Order book | ₹57 crore in deferred Gulf export orders recognized in Q1 FY27. |
| Demand visibility | Strong growth led by test-kit consumption across 12,500+ installed devices. |
| Management confidence | High; emphasizing milestone listing year and volume-led scale-up readiness. |
Growth
Q1 FY27 Revenue rose 310% YoY to ₹408.4 Cr; PAT turned positive at ₹52.7 Cr vs ₹(23.9) Cr loss.
Outlook
Capex underway for Bengaluru R&D and automation; pipeline of 34 additional assays across 22 diseases remains on track.
Risks
Non-linear revenue profile with performance varying across quarters; geopolitical issues in the Gulf caused order deferrals.
Investor Presentation filed with NSE, NSE: MOLBIO. Summary written with AI assistance from the document.
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,493.20
- Market cap
- ₹17,208 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- P/E (TTM)
- 111.5×Sector 55.1×
- Promoter holding
- 41.29%
- FII holding
- 1.59%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Molbio Diagnostics Ltd
All →Molbio Diagnostics Earnings Call Transcript: Key Takeaways
H1 FY27 revenue of ₹667 Cr was slightly below ₹680 Cr a year ago. Management blamed a one-month government rate-contract delay and reiterated 25% FY27 growth guidance.
- Call
- Guides 25% growth
Molbio Diagnostics Other Announcement
Molbio Diagnostics filed CRISIL's monitoring agency report on IPO proceeds utilisation for the quarter ended 30 September 2026. The report states no deviation from the issue objects.
Molbio Diagnostics Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹259 Cr (-55% YoY), PAT ₹7.7 Cr (-93%). H1 FY27 revenue ₹667 Cr (-2%), PAT ₹60 Cr (-27%). Management reiterates 25% FY27 topline growth target.
- Call
- Guides 25% growth
Molbio Diagnostics Q2 FY27 Results: Net Profit ₹7.7 Cr, Down 92.8% YoY
Molbio Diagnostics Ltd reported revenue from operations of ₹259 Cr (-55.4% YoY) and net profit of ₹7.7 Cr (-92.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.7 Cr · -92.8% YoY
Molbio Diagnostics Board Meeting Date
Molbio Diagnostics' Board is scheduled for November 5, 2026, to approve Q1 and H1 results. Trading window stays closed until 48 hours post-declaration.
Molbio Diagnostics Price Movement Clarification
Molbio Diagnostics responded to NSE's spurt-in-volume query, stating the movement is purely market-driven. No pending price-sensitive information is slated for disclosure.